Австралия - английский - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - efavirenz,emtricitabine,tenofovir disoproxil fumarate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; sodium chloride; dimethyl sulfoxide - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large b-cell lymphoma after two or more lines of systemic therapy, including diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl arising from follicular lymphoma. yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; dimethyl sulfoxide; sodium chloride - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (mcl), who have received two or more lines of therapy, including a btk inhibitor, unless ineligible or intolerant to treatment with a btk inhibitor.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of:large b-cell lymphoma - patients with relapsed or refractory large b-cell lymphoma (lbcl).yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. follicular lymphoma - patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - co-amoxiclav - granules for oral suspension - 312.5 mg

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - co-amoxiclav - film-coated tablet - 625 mg

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - co-amoxiclav - powder for oral suspension - 457 mg

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - co-amoxiclav - powder for injection (iv) - 1.2 g

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: biocare lifesciences, inc. - methylprednisolone (as sodium succinate) - powder for injection (iv) - 1g

Филиппины - английский - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: biocare lifesciences, inc. - paracetamol - solution for injection (iv infusion) - 10 mg/ml (1 g/100 ml)